Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN)

NCT03143491 is registered in ClinicalTrials.gov with DFB Soria, LLC as lead sponsor.

NCT NCT03143491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03143491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN)
Lead sponsor
DFB Soria, LLC
Phase
Phase 2
Overall status
Withdrawn
Start date
October 1, 2017
Completion date
March 1, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia